Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21272608 | 1.00 | GNRHR (0.41) | GNRHRSCN4ASLC6A2TACR1TRPM8 | |
| Hydrochloric Acid SCHEMBL28715422 | 0.98 | SLC6A2 (0.41) | GNRHRSCN4ASLC6A2 | |
| Hydrochloric Acid SCHEMBL28715420 | 0.98 | SLC6A2 (0.41) | GNRHRSCN4ASLC6A2 | |
| SCHEMBL22952644 | 0.87 | TACR1 (0.40) | GNRHRSCN4ASLC6A2TACR1 | |
| SCHEMBL22965301 | 0.87 | TACR1 (0.40) | GNRHRSCN4ASLC6A2TACR1 | |
| SCHEMBL22953366 | 0.86 | SCN4A (0.41) | SCN4ASLC6A2TACR1TRPM8 | |
| SCHEMBL22965295 | 0.86 | SCN4A (0.41) | SCN4ASLC6A2TACR1TRPM8 | |
| Hydrochloric Acid SCHEMBL28719359 | 0.85 | SLC6A2 (0.40) | GNRHRSCN4ASLC6A2TACR1 | |
| Hydrochloric Acid SCHEMBL28719363 | 0.85 | SLC6A2 (0.40) | GNRHRSCN4ASLC6A2TACR1 | |
| Hydrochloric Acid SCHEMBL28702853 | 0.85 | SCN4A (0.40) | SCN4ASLC6A2TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4007571-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES | H LUNDBECK AS (DK) | 2025-06-18 | — | — | EP | disclosed |
| EP-4241843-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H LUNDBECK AS (DK) | 2025-05-21 | — | — | EP | disclosed |
| US-12258305-B2 | Alcohol derivatives as Kv7 potassium channel openers | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| CN-119490430-A | Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures | H.隆德贝克有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-114206328-B | Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures | H.隆德贝克有限公司 | 2024-09-17 | — | — | CN | disclosed |
| EP-4241843-A2 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. Lundbeck A/S (DK) | 2023-09-13 | — | — | EP | disclosed |
| EP-4241843-A2 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. Lundbeck A/S (DK) | 2023-09-13 | — | — | EP | disclosed |
| CN-116589375-A | Alcohol derivatives as Kv7 potassium channel openers | H.隆德贝克有限公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-3755684-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| EP-3755684-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H LUNDBECK AS (DK) | 2023-07-12 | — | — | EP | disclosed |
| WO-2021023617-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2021-02-11 | — | — | WO | disclosed |
| US-20210032196-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2021-02-04 | — | — | US | disclosed |
| CN-111727182-A | Alcohol derivatives as Kv7 potassium channel openers | H.隆德贝克有限公司 | 2020-09-29 | — | — | CN | disclosed |
| US-20200172474-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2020-06-04 | — | — | US | disclosed |
| US-20200172474-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2020-06-04 | — | — | US | disclosed |
| US-10590067-B2 | Alcohol derivatives of carboxamides as Kv7 potassium channel openers | H. LUNDBECK A/S (DK) | 2020-03-17 | — | — | US | disclosed |
| WO-2019161877-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2019-08-29 | — | — | WO | disclosed |
| US-20190256456-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2019-08-22 | — | — | US | disclosed |
| US-20190256456-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H. LUNDBECK A/S (DK) | 2019-08-22 | — | — | US | disclosed |
| US-20160158132-A1 | Stabilization of Cosmetic Compositions | BASF SE (DE) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158132-A1 | Stabilization of Cosmetic Compositions | C1R, CBR1, CBR3 | GNRHR 1064/4885SCN4A 1550/4885SLC6A2 2842/4885 |
| US-20190256456-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | KCNA7, KCNK17, KCNQ1 | GNRHR 3573/4885SCN4A 67/4885SLC6A2 396/4885 |
| US-10590067-B2 | Alcohol derivatives of carboxamides as Kv7 potassium channel openers | KCNA7, KCNQ5, KCNQ1 | GNRHR 4232/4885SCN4A 82/4885SLC6A2 1191/4885 |
| US-20210032196-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | KCNA7, KCNK17, KCNQ1 | GNRHR 3573/4885SCN4A 67/4885SLC6A2 396/4885 |
| US-20200172474-A1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | KCNA7, KCNK17, KCNQ1 | GNRHR 3573/4885SCN4A 67/4885SLC6A2 396/4885 |
| US-12258305-B2 | Alcohol derivatives as Kv7 potassium channel openers | KCNA7, KCNK17, KCNQ1 | GNRHR 3573/4885SCN4A 67/4885SLC6A2 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.